Neuraceq® Scan

Neuraceq® delivers sensitive and reliable detection of β-amyloid neuritic plaques

Neuraceq® is an accurate diagnostic tool to aid in the evaluation of cognitive decline.1 Neuraceq® reveals β-amyloid neuritic plaques in different brain regions, thereby allowing an estimate of plaque density by degree of uptake.1

Negative Scans

Top row images are negative scans, corresponding to lower tracer uptake in gray matter than white matter, and reduced likelihood that cognitive decline is a result of AD

Visual assessment is based on the systematic comparison of tracer uptake in gray and white matter, focusing on specific cortical regions, as seen in greyscale images.

1Neuraceq® [prescribing information]. Life Molecular Imaging; 2024

Positive Scans

Images show positive scans with equal or higher tracer uptake in gray matter than white matter and moderate to frequent β-amyloid neuritic plaques

Neuraceq® scan reports can help facilitate dialogue between physicians, patients, and caregivers

While the actual diagnosis is made by reading the black and white scans, useful reports provided to you by your patient’s imaging specialist include an accompanying written assessment.

The Neuraceq® scan is convenient for patients

Neuraceq® provides a wide, stable scan window of 45-130 minutes, and a 15-20 minute scan time, making the process quick and convenient for your patients. A Neuraceq® PET scan involves an injection into a vein in the arm and a short scan.

Neuraceq Injection

Neuraceq® injection

45 mins

Wait 45+ minutes

PET scan

PET scan

Neuraceq brain scan

Scan completed

Frequently Asked Questions about Neuraceq®

Neuraceq® was FDA approved in March 2014 and is available in many imaging centers across the US.

Contact Us for specific details on Neuraceq® availability in your area or send an email to sales[at]life-mi.com.

Neuraceq® can give you important information in cases where Alzheimer’s disease is suspected. If the scan is positive, it means that beta amyloid plaques are present in the brain. If the scan is negative, it means that beta amyloid plaques are not present, and another diagnosis can be considered.

Early detection and intervention can benefit patients. Neuraceq® alone does not diagnose AD, it should be used in conjunction with other tests. Having a diagnosis gives patients the opportunity to plan ahead. Pharmacological and non-pharmacological interventions can begin sooner. Knowing a diagnosis gives patients the opportunity to take part in clinical trials.

Our patient and caregiver information can be viewed on our patient and caregiver page. If you would like a printed copy of the brochure, please contact 617-725-0070 or send an email to info[at]life-mi.com.

Contact Us for more information.